106797-69-7Relevant articles and documents
Synthesis of key intermediate of phosphonosulfonates (BPH-652), 1-(3-iodopropyl)-3-phenoxy benzene
Lu, Min,Zhou, Shuwen,Guan, Jing,Xu, Xing,Fan,Xu, Defeng
, p. 7619 - 7621 (2014)
A convenient and efficient four-step synthesis of 1-(3-iodopropyl)-3-phenoxy benzene can be achieved by 3-phenoxybenzaldehyde and malonic acid in the presence of piperidine and pyridine to yield (E)-3-(3-phenoxyphenyl)-2-propenoic acid, esterification with methanol in the present of p -toluene sulfonic acid, reduction with sodium borohydride to give 3-(3-phenoxyphenyl)propan-1-ol and iodination of 3-(3-phenoxy phenyl) propan-1-ol using iodine and triphenylphosphine in the present of potassium iodide and imidazole and to afford the title compound in an overall yield of 55.6 %.
Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors
Song, Lijun,Merceron, Romain,Gracia, Bego?a,Quintana, Ainhoa Lucía,Risseeuw, Martijn D. P.,Hulpia, Fabian,Cos, Paul,Aínsa, José A.,Munier-Lehmann, Hélène,Savvides, Savvas N.,Van Calenbergh, Serge
, p. 2753 - 2775 (2018/04/23)
In recent years, thymidylate kinase (TMPK), an enzyme indispensable for bacterial DNA biosynthesis, has been pursued for the development of new antibacterial agents including against Mycobacterium tuberculosis, the causative agent for the widespread infectious disease tuberculosis (TB). In response to a growing need for more effective anti-TB drugs, we have built upon our previous efforts toward the exploration of novel and potent Mycobacterium tuberculosis TMPK (MtTMPK) inhibitors, and reported here the design of a novel series of non-nucleoside inhibitors of MtTMPK. The inhibitors display hitherto unexplored interactions in the active site of MtTMPK, offering new insights into structure-activity relationships. To investigate the discrepancy between enzyme inhibitory activity and the whole-cell activity, experiments with efflux pump inhibitors and efflux pump knockout mutants were performed. The minimum inhibitory concentrations of particular inhibitors increased significantly when determined for the efflux pump mmr knockout mutant, which partly explains the observed dissonance.
Preparation method of 3-aryl propanol
-
Paragraph 0034; 0035, (2017/08/28)
The invention discloses a preparation method of 3-aryl propanol. According to the preparation method, 3-aryl benzaldehyde and acetate are dissolved into an organic solvent, a catalyst is added at a certain temperature to carry out condensation reactions to prepare 3-aryl-2-alkene ester, then 3-aryl-2-alkene ester and a reducing agent carry out reduction reactions to obtain the final product 3-aryl propanol. The provided method adopts aryloxy to replace benzaldehyde to carry out condensation reactions with acetate, and then the reaction product is reduced to prepare 3-aryl propanol. Aromatic aldehyde and acetate carry out condensation reactions in the presence of a catalyst to prepare a Knoevenagel like condensate namely 3-aryl-2-alkene ester, and then 3-aryl-2-alkene ester is reduced by a reducing agent to prepare aryl propanol. The total yield is greater than 80%. The content is more than 95%. The raw materials are cheap, and the sources are wide. The preparation method is safer and more convenient. Moreover, the production cost is low, the raw materials is nontoxic or little toxic, the total yield is high, the generated waste gas, waste water, and waste solid are little, and the industrialization is easy.
PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS
-
Paragraph 0113; 0119, (2016/12/01)
The present invention relates to novel compounds which are highly selective inhibitors of diacylglycerol lipase α and β. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-α (alternative name: Sn1-specific diacylglycerol hydrolase a; DAGL-α) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive ompounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity.
ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS
-
Page/Page column 24, (2012/02/03)
This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.
Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in staphylococcus aureus
Song, Yongcheng,Lin, Fu-Yang,Yin, Fenglin,Hensler, Mary,Poveda, Carlos A. Rodrígues,Mukkamala, Dushyant,Cao, Rong,Wang, Hong,Morita, Craig T.,Pacanowska, Dolores González,Nizet, Victor,Oldfield, Eric
experimental part, p. 976 - 988 (2009/12/04)
Staphylococcus aureus produces a golden carotenoid virulence factor called staphyloxanthin (STX), and we report here the inhibition of the enzyme, dehydrosqualene synthase (CrtM), responsible for the first committed step in STX biosynthesis. The most acti
Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: In vitro, in vivo, and crystallographic results
Song, Yongcheng,Liu, Chia-I.,Lin, Fu-Yang,Joo, Hwan No,Hensler, Mary,Liu, Yi-Liang,Jeng, Wen-Yih,Low, Jennifer,Liu, George Y.,Nizet, Victor,Wang, Andrew H.-J.,Oldfield, Eric
experimental part, p. 3869 - 3880 (2009/12/28)
The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first co
α-phosphonosulfinic squalene synthetase inhibitors
-
, (2008/06/13)
α-Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula STR1 wherein R2 is OR5 or R5a ; R3 and Rsu
Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
-
, (2008/06/13)
α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula STR1 wherein R2 is OR5 or R5a ; R3 and R5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.
Synthesis and biological activity of new 3-hydroxy-3-methylglutaryl-CoA synthase inhibitors: 2-Oxetanones with a meta-substituent on the benzene ring in the side chain
Hashizume,Ito,Kanaya,Nagashima,Usui,Oshima,Kanao,Tomoda,Sunazuka,Kumagai,Omura
, p. 1272 - 1278 (2007/10/02)
Isosteric side chain analogs of 3a were synthesized and tested for inhibitory activities towards 3-hydroxy-3-methylglutaryl coenzyme A (HMG- CoA) synthase and upon cholesterol production in Hep G2 cells and in mouse liver. It became clear that the lipophi
